---
document_datetime: 2024-01-10 16:18:09
document_pages: 11
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/latuda-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: latuda-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 7.1340441
conversion_datetime: 2025-12-28 00:12:52.572161
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Latuda

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IA/0042              | A.7 - Administrative change - Deletion of manufacturing sites | 09/01/2024                          |                                             | Annex II and PL                  |           |
| IB/0040/G            | This was an application for a group of variations.            | 08/08/2023                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products   |            |            |                        | arrangements   |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------|
| IA/0039 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                               | 10/11/2022 | n/a        |                        |                |
| IA/0038 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                              | 21/10/2022 | n/a        |                        |                |
| II/0037 | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                             | 10/03/2022 | n/a        |                        |                |
| II/0036 | Update of section 4.8 of the SmPC to amend the frequency of ADRs in adults and to add 'syncope' (frequency uncommon) and 'cerebrovascular accident' (frequency rare) following the assessment of the procedure EMEA/H/C/PSUSA/00010114/202010. The Package                                                                                                 | 02/12/2021 | 18/11/2022 | SmPC, Labelling and PL |                |

<div style=\"page-break-after: always\"></div>

|                     | Leaflet is updated accordingly. Minor adjustments of the PTs based on the MedDRA definitions were implemented and the ADR 'blood creatine phosphokinase increased' was moved to the SOC Investigations. In addition, the marketing authorisation holder has taken the opportunity to combine all the dosages in a single version of the SmPC, to update the list of local representatives in the PL and to bring the PI in line with the latest QRD template version 10.2 Rev. 1. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH   |            |            |                 |                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------------------------------------|
| PSUSA/10114 /202010 | Periodic Safety Update EU Single assessment - lurasidone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 10/06/2021 | n/a        |                 | PRAC Recommendation - maintenance                          |
| II/0033             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 11/03/2021 | n/a        |                 |                                                            |
| IA/0035             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 02/03/2021 | 25/10/2021 | Annex II and PL |                                                            |
| N/0032              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 08/01/2021 | 25/10/2021 | PL              |                                                            |
| II/0029             | Extension of Indication for the treatment of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 23/07/2020 | 25/08/2020 | SmPC and PL     | Please refer to Scientific Discussion 'Latuda-H-C-2713-II- |

<div style=\"page-break-after: always\"></div>

|           | schizophrenia in adolescent from 13 years and over; as a consequence, sections 4.1, 4.2, 4.8, 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 8.1 of the RMP has also been agreed. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. Furthermore, the PI is brought in line with the latest excipient guideline. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |            |             | Var.29'.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------|
| IB/0031   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 21/08/2020 | 25/10/2021 | SmPC and PL |            |
| N/0030    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 24/03/2020 | 25/08/2020 | PL          |            |
| IAIN/0028 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 23/10/2019 | n/a        |             |            |
| N/0027    | Minor change in labelling or package leaflet not                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 16/07/2019 | 17/10/2019 | PL          |            |

<div style=\"page-break-after: always\"></div>

|             | connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                           |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0026   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                    | 18/03/2019 | 17/10/2019 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| N/0025      | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                          | 11/01/2019 | 17/10/2019 | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0022     | Update of section 4.5 of the SmPC in order to update the safety information following literature review regarding drug interaction between a strong CYP3A4 inhibitor (i.e.posaconazole) and lurasidone. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 13/12/2018 | 17/10/2019 | SmPC                             | Further to the review of literature data where 11 healthy subjects were coadministered lurasidone and posaconazole (strong CYP3A4 inhibitor) resulting in an approximate 4-5 fold increase in lurasidone exposure and a persistent effect of posaconazole on lurasidone (up to 2-3 weeks after stop of co-administration), the CHMP agreed to update the SmPC of Latuda in order to reflect new drug interactions between a strong CYP3A4 inhibitor (i.e.posaconazole) and lurasidone. |
| R/0020      | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                   | 20/09/2018 | 14/11/2018 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Latuda in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                                                                                                                                                                                                                   |
| IAIN/0024/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                     | 23/10/2018 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0023 | B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 23/10/2018 | 17/10/2019 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0021   | Update of sections 5.1 of the SmPC to add new paediatric data available in children and adolescent patients (10-17 years of age) with bipolar I disorder, upon request by CHMP following the assessment of the paediatric study D1050326 submitted according to Art. 46 procedure (no. EMEA/H/C/002713/P46/008). In addition, section 4.2 of the SmPC has been updated to cross refer to section 5.1. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH | 18/10/2018 | 17/10/2019 | SmPC            | For study D1050326 the primary efficacy endpoint was defined as the mean change from baseline to Week 6 in Children's Depression Rating Scale, Revised (CDRS-R) Total Score. The key secondary endpoint was Clinical Global Impression - Bipolar Version, Severity of Illness (CGI-BP- S) Depression Score. Statistically significant differences favouring lurasidone over placebo were shown for these endpoints for the total population studied, beginning at Week 2 and were maintained at each study visit through to the end of the study. However, the primary and key secondary efficacy endpoints were not met in younger patients (below 15 years of age). The safety profile of lurasidone in children included in this short-term study is in general consistent with that observed when treated within the approved indication in adults, however, differences in frequency of the most commonly occurred adverse reactions have been observed in paediatric patients for nausea (very common), diarrhoea (common) and decreased appetite (common), compared with adults (common, unknown, and uncommon, respectively). Based on these paediatric data sections 4.2 and 5.1 of the SmPC have been updated accordingly. |

<div style=\"page-break-after: always\"></div>

| PSUSA/10114 /201710   | Periodic Safety Update EU Single assessment - lurasidone                                                                                                                                                                                                                                                                                                                                     | 17/05/2018   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                          |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| T/0019                | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                          | 21/02/2018   | 12/03/2018 | SmPC, Labelling and PL |                                                                                                                                            |
| PSUSA/10114 /201610   | Periodic Safety Update EU Single assessment - lurasidone                                                                                                                                                                                                                                                                                                                                     | 18/05/2017   | 13/07/2017 | SmPC and PL            | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10114/201610. |
| II/0016               | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                                                                                                                                | 06/07/2017   | n/a        |                        |                                                                                                                                            |
| N/0017                | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                             | 30/05/2017   | 12/03/2018 | PL                     |                                                                                                                                            |
| PSUSA/10114 /201510   | Periodic Safety Update EU Single assessment - lurasidone                                                                                                                                                                                                                                                                                                                                     | 13/05/2016   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                          |
| IAIN/0014/G           | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing | 10/03/2016   | 22/03/2017 | Annex II and PL        |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| T/0013              | Marketing Authorisation transfer from Takeda Pharma A/S to Sunovion Pharmaceuticals Europe Ltd. Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                     | 28/01/2016   | 15/02/2016   | Labelling and PL   |                                                                                                                                                                                                                  |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10114 /201504 | Periodic Safety Update EU Single assessment - lurasidone                                                                                                                                                                                                                                                                                                                                                                                                                                | 19/11/2015   | 11/01/2016   | SmPC and PL        | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10114/201504.                                                                       |
| IAIN/0011           | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                         | 08/01/2016   | n/a          |                    |                                                                                                                                                                                                                  |
| IAIN/0010           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                      | 10/12/2015   | n/a          |                    |                                                                                                                                                                                                                  |
| II/0009             | Update of section 4.8 of the SmPC to include the ADR Stevens-Johnson Syndrome, and to include information regarding serious cases of skin and other hypersensitivity reactions reported in the post- marketing setting. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to make a minor correction in section 5.1 of the SmPC. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 22/10/2015   | 11/01/2016   | SmPC and PL        | Post marketing reports of clinically serious cases of skin and other hypersensitivity reactions have been reported in association with lurasidone treatment, including some reports of Stevens-Johnson syndrome. |

<div style=\"page-break-after: always\"></div>

| IB/0008             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 08/09/2015   | 11/01/2016   | SmPC and PL   |                                                                                                                                                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0006/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of | 24/07/2015   | n/a          |               |                                                                                                                                                                   |
| PSUSA/10114 /201410 | Periodic Safety Update EU Single assessment - lurasidone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 21/05/2015   | 17/07/2015   | SmPC and PL   | Please refer to Latuda-PSUSA-00010114-201410 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation      |
| II/0003/G           | This was an application for a group of variations. Update of section 5.2 of the SmPC with new CYP                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 26/03/2015   | 17/07/2015   | SmPC          | In vitro, lurasidone demonstrated no direct, or weak inhibition (direct or time-dependent) (IC50>5.9 Î¼M) of the enzymes cytochrome P450 (CYP)1A2, CYP2B6, CYP2C8, |

<div style=\"page-break-after: always\"></div>

|           | inhibition data based on three non-clinical in vitro studies (GE-1267/GE-1284-G, AE-7394-G and PCA 14340) undertaken to fulfil post-authorisation measures (RECs) agreed at the time of the initial MAA. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |            |             | CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. Based on this data, lurasidone is not expected to affect the pharmacokinetics of medicinal products that are substrates of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0005   | To update sections 4.2 and 5.2 of the SmPC to include data from study D1050300 on the approved lurasidone PIP for schizophrenia. In addition the MAH took this opportunity to update the local representatives in Greece and Finland. Finaly, minor editorial amendments were performed in the annexes of the following languages: CS, DA, DE, FR, PT, NO and SV C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                      | 18/02/2015 | 17/07/2015 | SmPC and PL |                                                                                                                                                                                                                                        |
| PSUV/0002 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/11/2014 | 15/01/2015 | SmPC and PL | Refer to Scientific conclusions and grounds recommending                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                           |            |            |                        | the variation to terms of the Marketing Authorisation(s)' for PSUV/0002.   |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------|
| IB/0001 | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 04/07/2014 | 15/01/2015 | SmPC, Labelling and PL |                                                                            |